Literature DB >> 3582496

The effect of nalbuphine on gastrointestinal transit in mice.

C L Wong.   

Abstract

Nalbuphine given subcutaneously (s.c.) inhibited gastrointestinal transit in a dose-dependent manner. Prior s.c. administration of naloxone hydrochloride suppressed the inhibitory effect of nalbuphine on gastrointestinal transit. Naloxone methobromide (naloxone MB), a quaternary compound, was also effective in antagonising this effect of nalbuphine but was less effective than naloxone hydrochloride. Furthermore, prior s.c. administration of Mr 2266 also antagonised the gastrointestinal transit inhibitory action of nalbuphine. When given centrally, either intracerebroventricularly (i.c.v.) or intracisternally (i.c.), naloxone hydrochloride was ineffective in antagonising s.c. nalbuphine. Similar findings were observed with centrally administered Mr 2266. In addition, i.c. nalbuphine had a minimal effect on gastrointestinal transit while i.c.v. nalbuphine only caused slight inhibition of gastrointestinal transit. It was concluded that nalbuphine inhibits gastrointestinal transit mainly through peripheral opiate receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582496     DOI: 10.1016/0014-2999(87)90614-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

Review 1.  Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice.

Authors:  Heather Lyons Narver
Journal:  Lab Anim (NY)       Date:  2015-03       Impact factor: 12.625

2.  Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.

Authors:  Brenda L Kick; Pan Shu; Bo Wen; Duxin Sun; Douglas K Taylor
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-09-01       Impact factor: 1.232

3.  Inhibition of gastrointestinal motility by MPTP via adrenergic and dopaminergic mechanisms.

Authors:  Y Haskel; M Hanani
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.